158406-99-6

Basic information

• Product Name: (S)-tert-Butyl 3-(bromomethyl)piperidine-1-carboxylate
• Synonyms: (S)-tert-Butyl 3-(bromomethyl)piperidine-1-carboxylate ;(S)-1-Boc-3-broMoMethylpiperidine;(S)-3-Bromomethyl-piperidine-1-carboxylic acid tert-butyl ester;tert-butyl (3S)-3-(bromomethyl)piperidine-1-carboxylate
• CAS NO: 158406-99-6
• Molecular Formula: C₁₁H₂₀BrNO₂
• Molecular Weight: 278.2
• Mol File: 158406-99-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 318.3±15.0 °C(Predicted)
• Appearance: /
• Density: 1.270±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -2.03±0.40(Predicted)
• CAS DataBase Reference: (S)-tert-Butyl 3-(bromomethyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-Butyl 3-(bromomethyl)piperidine-1-carboxylate(158406-99-6)
• EPA Substance Registry System: (S)-tert-Butyl 3-(bromomethyl)piperidine-1-carboxylate(158406-99-6)

Safety Data

• Hazardous Substances Data: 158406-99-6(Hazardous Substances Data)

Usage

General Description

"(S)-tert-Butyl 3-(bromomethyl)piperidine-1-carboxylate" is a chemical compound with the molecular formula C13H23BrNO2. It is a piperidine derivative that contains a tert-butyl group and a bromomethyl group. (S)-tert-Butyl 3-(bromomethyl)piperidine-1-carboxylate is commonly used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It has potential applications in the field of medicinal chemistry, particularly in the development of new drugs and treatments. Additionally, it may also be used as a reagent in organic chemical reactions due to its unique structural features. Overall, "(S)-tert-Butyl 3-(bromomethyl)piperidine-1-carboxylate" is a versatile compound with promising uses in various chemical and pharmaceutical applications.

Upstream product

• 364356-44-5 (S)-<<(methylsulfonyl)oxy>methyl>piperidine-1-carboxylic acid tert-butyl ester 
• 116574-71-1 tert-butyl (3R)-3-(hydroxymethyl)piperidine-1-carboxylate 
• 140695-84-7 tert-butyl (3S)-3-(hydroxymethyl)piperidine-1-carboxylate 

Downstream Products

• 937174-75-9 1,1-dimethylethyl (3S)-3-({[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy}methyl)-1-piperidinecarboxylate 
• 937174-76-0 GSK₆₉₀₆₉₃ 
• 1039361-80-2 C₁₂H₂₀N₂O₂ 
• 937174-74-8 1,1-dimethylethyl (3S)-3-({[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy}methyl)-1-piperidinecarboxylate 

Relevant articles and documents

Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis

Bruton's tyrosine kinase (Btk) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) and Fcγ receptor (FcR) signaling pathways, which makes it a uniquely attractive target for the treatment of autoimmune diseases, such as rheumatoid arthritis (RA). We reported a series of compounds bearing 7H-pyrrolo [2,3-d]pyrimidin-4-amine scaffold that potently inhibited Btk in vitro. Analysis of the structure-activity relationships (SAR) and drug-like profiles led to the discovery of the optimal compound B16. B16 preferentially inhibited Btk (IC50 = 21.70 ± 0.82 nM) over closely related kinases with moderate selectivity. Cell-based tests also confirmed that B16 significantly inhibited Btk Y223 auto-phosphorylation and PLCγ2 Y1217 phosphorylation. MTT revealed that B16 displayed weak suppression against normal LO2, HEK293 and THP-1 cell lines with IC50 values over 30 μM. Moreover, B16 showed very weak potential to block the hERG channel (IC50 = 11.10 μM) in comparison to ibrutinib (IC50 = 0.97 μM). Owing to its favorable physicochemical properties (ClogP = 2.53, aqueous solubility ≈ 0.1 mg/mL), pharmacokinetic profiles (F = 49.15%, t1/2 = 7.02 h) and reasonable CYP450 profile, B16 exhibited potent anti-arthritis activity and similar efficacy to ibrutinib in reducing paw thickness in CIA mice. In conclusion, B16 is a potent, selective and durable inhibitor of Btk and has the potential to a safe and efficacious treatment for arthritis.

METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY

Invented is the use of 1 H-imidazo[4,5-c]pyridin-2-yl compounds in the treatment of specified cancers.

INHIBITORS OF AKT ACTIVITY

Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.